Age-related Macular Degeneration (AMD) is a severe eye disease and major cause of vision loss in elderly. AMD inhibits the ability to see objects directly ahead and causes irreversible, progressive decline in an individual’s independence and ability to perform daily activities. Across the EU, 17.1 million people are living with AMD, of which 2.5 million cases are the costlier late stage AMD. The total cost of managing the consequences is expected to be € 89.46 billion per year. New research found that savings of € 6.20 billion a year could be generated through the daily consumption of lutein and zeaxanthin.
Expert Insights You Won’t Want to Miss: